Pfizer Inc. (NYSE:PFE) Shares Bought by Mittelman Wealth Management

Mittelman Wealth Management grew its holdings in Pfizer Inc. (NYSE:PFE) by 53.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,016 shares of the biopharmaceutical company’s stock after purchasing an additional 4,166 shares during the period. Mittelman Wealth Management’s holdings in Pfizer were worth $336,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of PFE. Gilbert & Cook Inc. boosted its position in shares of Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 945 shares during the period. Gryphon Financial Partners LLC boosted its position in shares of Pfizer by 43.7% during the fourth quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after buying an additional 8,194 shares during the period. Quest Partners LLC purchased a new position in shares of Pfizer during the fourth quarter worth $186,000. Aigen Investment Management LP acquired a new stake in shares of Pfizer in the fourth quarter valued at $867,000. Finally, InterOcean Capital Group LLC raised its holdings in shares of Pfizer by 5.3% in the 4th quarter. InterOcean Capital Group LLC now owns 25,864 shares of the biopharmaceutical company’s stock valued at $745,000 after buying an additional 1,291 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.3 %

Pfizer stock opened at $29.75 on Thursday. The stock’s fifty day moving average is $29.33 and its two-hundred day moving average is $28.19. The stock has a market cap of $168.58 billion, a PE ratio of -495.75, a P/E/G ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.65%. The ex-dividend date was Friday, July 26th. Pfizer’s payout ratio is -2,799.53%.

Analysts Set New Price Targets

A number of brokerages recently commented on PFE. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday. Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group upped their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.